1′-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL

Biochemical and Biophysical Research Communications

Volumn 338, Issue 4, 2005, Pages 1702-1710

  Ito, Keisuke ^a   Nakazato, Tomonori ^a   Murakami, Akira ^b   Ohigashi, Hajime ^b   Ikeda, Yasuo ^a   Kizaki, Masahiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

1 Acetoxychavicol acetate; Apoptosis; Multiple myeloma; TRAIL

Indexed keywords

1' ACETOXYCHAVICOL ACETATE; CASPASE 8; DEATH RECEPTOR; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; 1'-ACETOXYCHAVICOL ACETATE; APOPTOSIS REGULATORY PROTEIN; INTERLEUKIN 6; MEMBRANE PROTEIN; TERPENE; TNFRSF10B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHIMERA; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME INACTIVATION; ETHNOPHARMACOLOGY; HUMAN; HUMAN CELL; MEDICINAL PLANT; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION; ZINGIBERACEAE; BIOSYNTHESIS; BONE MARROW CELL; DRUG ANTAGONISM; DRUG EFFECT; MULTIPLE MYELOMA; PATHOLOGY; TUMOR CELL LINE;

ALPINIA GALANGA; ZINGIBERACEAE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TERPENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27844602024     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.10.153     Document Type: Article

References (31)

1. A. Kondo, H. Ohigashi, A. Murakami, S. Jiwajinda, and K. Koshimizu A potent inhibitor of tumor promoter-induced Epstein-Barr virus activation, 1′-acetoxychavicol acetate from Languas galangal, a traditional Thai condiment Biosci. Biotech. Biochem. 57 1993 1344 1345
2. A. Nakamura, Y. Murakami, K. Ohto, T. Torikai, T. Tanaka, and H. Ohigashi Suppression of tumor promoter-induced oxidative stress and inflammatory responses in mouse skin by a superoxide generation inhibitor 1′-acetoxychavicol acetate Cancer Res. 58 1998 4832 4839
3. A. Murakami, S. Ohura, Y. Nakamura, K. Koshimizu, and H. Ohigashi 1′-acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin Oncology 53 1996 386 391
4. T. Tanaka, H. Makita, T. Kawamori, K. Kawabata, H. Mori, A. Murakami, K. Satoh, A. Hara, H. Ohigashi, and K. Koshimizu 1′-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats Carcinogenesis 18 1997 1113 1118
5. T. Tanaka, K. Kawabata, M. Kakumoto, H. Makita, K. Matsunaga, H. Mori, K. Satoh, A. Hara, A. Murakami, K. Koshimizu, and H. Ohigashi Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor 1′-acetoxychavicol acetate Jpn. J. Cancer Res. 88 1997 821 830
6. K. Ito, T. Nakazato, A. Murakami, K. Yamato, Y. Miyakawa, T. Yamada, N. Hozumi, H. Ohigashi, Y. Ikeda, and M. Kizaki Induction of apoptosis in human myeloid leukemic cells by 1′-acetoxychavicol acetate through a mitochondrial- and Fas-mediated dual mechanism Clin. Cancer Res. 10 2004 2120 2130
7. K. Ito, T. Nakazato, M.J. Xian, T. Yamada, N. Hozumi, A. Murakami, H. Ohigashi, Y. Ikeda, and M. Kizaki 1′-acetoxychvicol acetate is a novel nuclear factor-κB inhibitor with significant activity against multiple myloma in vitro and in vivo Cancer Res. 65 2005 4417 4424
8. T. Hideshima, and K.C. Anderson Molecular mechanism of novel therapeutic approaches for multiple myeloma Nat. Rev. Cancer 2 2002 927 937
9. S. Iida, and R. Ueda Multistep tumorigenesis of multiple myeloma: its molecular delineation Int. J. Hematol. 77 2003 207 212
10. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E.J. Feuer, and M.J. Thun Cancer statistics, 2004 CA Cancer J. Clin. 58 2004 8 29
11. M. Attal, J.L. Harousseau, A.M. Stoppa, J.J. Sotto, J.G. Fuzibet, J.F. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, C. Payen, and R. Bataille A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N. Engl. J. Med. 335 1996 91 97
12. A. Kumar, T. Loughran, M. Alsina, B.G. Durie, and B. Djulbegovic Management of multiple myeloma: a systemic review and critical appraisal of published studies Lancet Oncol. 4 2003 293 304
13. P.G. Richardson, P. Sonneveld, M.W. Schuster, T. Facon, J.L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J.F. San-Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W.S. Dalton, A.L. Boral, D.L. Esseltine, J.B. Porter, D. Schenkein, and K.C. Anderson Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 352 2005 2487 2498
14. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155 162
15. A. Ashkenazi, and V. Dixit Death receptors: signaling and modulation Science 281 1998 1305 1308
16. C.S. Mitsiades, S.P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K.C. Anderson TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications Blood 98 2001 795 804
17. D. Chauhan, P. Pandey, T. Hideshima, S. Treon, N. Raje, F.E. Davies, Y. Shima, Y.T. Tai, S. Rosen, S. Avraham, S. Kharbanda, and K.C. Anderson SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells J. Biol. Chem. 275 2000 27845 27850
18. N. Mitsiades, S. Constantine, S. Mitsiades, V. Poulaki, K.C. Anderson, and S.P. Treon Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma Blood 99 2002 2162 2171
19. A. Murakami, K. Toyota, S. Ohura, K. Koshimizu, and H. Ohigashi Structure-activity relationships of (1′S)-1′-acetoxychavicol acetate, a major constituent of a Southeast Asia condiment plant Langus galangal, on the inhibition of tumor-promoter-induced Epstein-Barr virus activation J. Agric. Food Chem. 48 2000 1518 1523
20. S.I. Pai, G.S. Wu, N. Ozoren, L. Wu, J. Jen, D. Sidransky, and W.S. El-Deiry Rare loss-of-function mutation of a death receptor gene in head and neck cancer Cancer Res. 58 1998 3513 3518
21. S.H. Lee, M.S. Shin, H.S. Kim, H.K. Lee, W.S. Park, S.Y. Kim, J.H. Lee, S.Y. Han, J.Y. Park, R.R. Oh, J.J. Jang, J.Y. Han, J.Y. Lee, and N.J. Yoo Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers Cancer Res. 59 1999 5683 5686
22. R. Feinman, J. Koury, M. Thames, B. Barlogie, J. Epstein, and D.S. Siegel Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2 Blood 93 1999 3044 3052
23. D. Chauhan, H. Uchiyama, Y. Akbarali, M. Urashima, K. Yamamoto, T.A. Libermann, and K.C. Anderson Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB Blood 87 1996 1104 1112
24. T. Hideshima, P.L. Bergsagel, W.M. Kuel, and K.C. Anderson Advances in biology of multiple myeloma: clinical applications Blood 104 2004 607 618
25. C.S. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, D. Chauhan, T. Hideshima, S.P. Treon, N.C. Munshi, P.G. Richardson, and K.C. Anderson Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications Oncogene 21 2002 5673 5683
26. W.J. Chng, L.G. Lau, N. Yusof, and B.M. Mow Targeted therapy in multiple myeloma Cancer Control 12 2005 91 104
27. N. Mitsiades, S. Constantine, S. Mitsiades, V. Poulaki, D. Chauhan, P.G. Richardson, T. Hideshima, N. Munshi, S.P. Treon, and K.C. Anderson Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications Blood 99 2002 4079 4086
28. M. Ohnishi, T. Tanaka, H. Makita, T. Kawamori, H. Mori, K. Satoh, A. Hara, A. Murakami, H. Ohigashi, and K. Koshimizu Chemopreventive effect of xanthine oxidase inhibitor, 1′-acetoxychavicol acetate, on rat oral carcinogenesis Jpn. J. Cancer Res. 87 1996 349 356
29. J. Moffatt, M. Hashimoto, A. Kojima, D.P. Kennedy, A. Murakami, K. Koshimizu, H. Ohigashi, and I. Matsui-Yuasa Apoptosis induced by 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells is associated with modulation of polyamine metabolism and caspase-3 activation Carcinogenesis 21 2000 2151 2157
30. H.N. LeBlanc, and A. Ashkenazi Apo2L/TRAIL and its death and decoy receptors Cell Death Differ. 10 2003 66 75
31. S.K. Kelley, L.A. Harris, D. Xie, L. Defforge, K. Totpal, J. Bussiere, and J.A. Fox Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmacol. Exp. Ther. 299 2001 31 38